Chung H, Watanabe T, Kudo M, <u>Chiba T.</u>	Correlation between hyporesponsiveness to Toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infection	J Viral Hepat	18	e561-567	2011
Nasu A, Marusawa H, Ueda Y, Nishijima N, Takahashi K, Osaki Y, Yamashita Y, Inokuma T, Tamada T, Fujiwara T, Sato F, Shimizu K, <u>Chiba T.</u>	Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing.	PLos One	6	e24907	2011
Kim SK, Marusawa H, Eso Y, Nishikawa H, Ueda Y, Kita R, Kimura T, <u>Chiba T,</u> Osaki Y, Kudo M	Clinical characteristics of non-B non-C hepatocellular carcinoma: A single-center retrospective study	Digestion	84	43-49	2011
Kawaoka T, Takahashi S, Tatsukawa Y, Hiramatsu A, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ide K, Tashiro H, <u>Ohdan H,</u> Chayama K.	Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation.	Hepatol Res.	In press		2014
Egawa H, Teramukai S, Haga H, Tanabe M, Mori A, Ikegami T, Kawagishi N, <u>Ohdan H,</u> Kasahara M, Umeshita K.	Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study.	Am J Transplant.	14(1)	102-14.	2014
<u>Ohdan H.</u>	Is living donor liver transplantation really equivalent to deceased donor liver transplantation?	Transpl Int.	26(8)	778-9.	2013

Ohira M, Nishida S, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, Tekin A, Selvaggi G, Levi D, Ruiz P, Ricordi C, <u>Ohdan H</u>, Tzakis AG.	Comparative analysis of T-cell depletion method for clinical immunotherapy-anti-hepatitis c effects of natural killer cells via interferon-γ production.	Transplant Proc.	45(5)	2045-50.	2013
Onoe T, Tanaka Y, Ide K, Ishiyama K, Oshita A, Kobayashi T, Amano H, Tashiro H, <u>Ohdan H</u>.	Attenuation of portal hypertension by continuous portal infusion of PGE1 and immunologic impact in adult-to-adult living-donor liver transplantation.	Transplantation	95(12)	1521-7.	2013
Morooka Y, Umeshita K, Taketomi A, Shirabe K, Maehara Y, Yamamoto M, Shimamura T, Oshita A, Kanno K, <u>Ohdan H</u>, Kawagishi N, Satomi S, Ogawa K, Hagiwara K, Nagano H.	Reliability and validity of a new living liver donor quality of life scale.	Surg Today	43(7)	732-40.	2013
<u>大段秀樹</u>	State of the Art 肝免疫と肝臓外科 Liver Immunity and Surgery.	Frontiers in Gastroenterology.	18(3)	203-213.	2013
尾上隆司, 高橋祥一，茶山一彰, <u>大段秀樹</u>	【肝移植-現状と展望】B型肝炎、肝硬変に対する肝移植	臨床消化器内科.	28(9)	1271-77.	2013
Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, <u>Ohdan H</u>, Chayama K	Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation	J Gastroenterol Hepatol	27(9)	1467-1472	2012

Okazaki A, Hiraga N, Imamura M, Hayes CN, Tsuge M, Takahashi S, Aikata H, Abe H, Miki D, Ochi H, Tateno C, Yoshizato K, Ohdan H, Chayama K.	Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse	Hepatology	56(2)	555-66	2012
Kawaoka T, Hiraga N, Takahashi S, Takaki S, Tsuge M, Nagaoki Y, Hashimoto Y, Katamura Y, Miki D, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Ochi H, Tashiro H, Ohdan H, Chayama K.	Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon α-2b to α-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report.	Intervirology	55(4)	306-310	2012
Tanaka Y, Tashiro H, Onoe T, Ide K, Ishiyama K, Ohdan H.	Optimization of immunosuppressive therapy based on a multiparametric mixed lymphocyte reaction assay reduces infectious complications and mortality in living donor liver transplant recipients.	Transplant Proc.	44(2)	555-59	2012
Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T, Chayama K, Ohdan H.	Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection	Ann Surg Oncol	19(2)	418-425	2011
Yanai H, Chiba S, Ban T, Nakaima Y, Onoe T, Honda K, Ohdan H, Taniguchi T.	Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs)	Transplantation	92(5)	575-80	2011

Tashiro H, Ishiyama K, Ohira M, Igarashi Y, Tahara H, Ide K, Onoe T, Tanaka Y, Ohdan H.	Impact of adjuvant immunotherapy using liver allograft-derived lymphocytes on bacteremia in living-donor liver transplantation	Transplantation	92(5)	575-580	2011
Kawaoka T, Aikata H, Miyaki D, Murakami E, Azakami T, Takaki S, Nagaoki Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K.	Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region	Hepatol Res	41(11)	1126-1131	2011
Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K.	IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma	J Viral Hepat	18(10)	e550-60	2011

Takamura H, Nakanuma S, Hayashi H, Tajima H, Kakinoki K, Sakai S, Makino I, Nakagawara H, Miyashita T, Okamoto K, Nakamura K, Oyama K, Inokuchi M, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Ohnishi I, Kayahara M, Tani T, Arai K, Yamashita T, Kitamura H, Ikeda H, Kaneko S, Nakanuma Y, Matsui O, <u>Ohta T.</u>	Evaluation of eligibility criteria in living donor liver transplantation for hepatocellular carcinoma by α-SMA positive cancer associated fibroblast.	Oncology Report	30	1561-1574	2013
Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Yamashita T, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW, Kaneko S.	Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.	Hepatology	57	1484-1497	2013
Hodo Y, Honda M, Tanaka A, Nomura Y, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Sakai A, Sasaki M, Nakanuma Y, Moriyama M, Kaneko S.	Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C.	Clin Cancer Res	19	1827-1837	2013

|					
Yamashita T1, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, Ohno N, Miyati T, Okada H, Yamashita T, Mizukoshi E, Honda M, Nakanuma Y, Takamura H, Ohta T, Nakamoto Y, Yamamoto M, Takayama T, Arii S, Wang XW, Kaneko S.	Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma.	Hepatology	In press		2014
Marubashi S, Mori S, et al.	Laparoscopy-assisted hybrid left-side donor hepatectomy.	World J Surg	37 (9)	2202- 2210	2013
Kobayashi S, Mori S, et al.	Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period.	Cancer Chemother Pharmacol	72(6)	1325-1333	2013
Marubashi S, Mori S, et al.	Hepatic artery reconstruction in living donor liver transplantation: risk factor analysis of complication and a role of MDCT scan for detecting anastomotic stricture.	World J Surg	37(11)	2671-2677	2013
Kim C, Mori M, et al.	Significance of Alanine Aminopeptidase N (APN) in Bile in the Diagnosis of Acute Cellular Rejection After Liver Transplantation	J Surg Res	178(2)	1003-1114	2012
Marubashi S, Mori M, et al.	Efficacy of Minimal Dosage of Calcineurin Inhibitor for Living Donor Liver Transplant Recipients with Preoperative Renal Dysfunction	Hepatogastroenterol	58(106)	508-511	2011

Marubashi S, Mori M, et al.	Donor hepatectomy for living donor liver transplantation: learning steps and surgical outcome	Dig Dis Sci	56(8)	2482-2490	2011
Kobayashi S, Mori M, et al.	Successful adult ABO incompatible living donor liver transplantation: Experience with double infusion through the hepatic artery and portal vein.	Hepatogastronetero l	58(106)	503-507	2011
永野浩昭, 森 正樹, 他	脳死肝移植の現状と問題点－これからの脳死移植 －	日消病誌	108(5)	735-742	2011
Kume H, Muraoka S, Kuga T, Adachi J, Narumi R, Watanabe S, Kuwano M, Kodera Y, Matsushita K, Fukuoka J, Masuda T, Ishihama Y, Matsubara H, Nomura F, Tomonaga T.	Discovery of colorectal cancer biomarker candidates by membrane proteomic analysisand subsequent verification using selected reaction monitoring and tissue microarrayanalysis.	Mol Cell Proteomics	in press		2014
Kuga T, Kume H, Kawasaki N, Sato M, Adachi J, Shiromizu T, Hoshino I, Nishimori T, Matsubara H and Tomonaga T.	A novel mechanism of keratin cytoskeleton organization through casein kinase I α and FAM83H in colorectal cancer.	Journal of cell science	126 (20)	4721-4731	2013
Shiromizu T, Adachi J, Watanabe S, Murakami T, Kuga T, Muraoka S, and Tomonaga T.	Identification of Missing Proteins in the neXtProt Database and Unregistered Phosphopeptides in the PhosphoSitePlus Database As Part of the Chromosome-Centric Human Proteome Project.	Journal of Proteome Research	12 (6)	2414-2421	2013

Muraoka S, Kume H, Adachi J, Shiromizu T, Watanabe S, Masuda T, Ishihama Y, and Tomonaga T	In-depth Membrane Proteomic Study of Breast Cancer Tissues for the Generation of a Chromosome-based Protein List.	Journal of Proteome Research	12 (1)	208-213	2013
Narumi R, Tatsuo Murakami, Kuga T, Adachi J, Shiromizu T, Muraoka S, Kume H, Kodera Y, Matsumoto M, Nakayama K, Miyamoto Y, Ishitobi M, Inaji H, Kato K and Tomonaga T.	A Strategy for Large-Scale Phosphoproteomics and SRM-Based Validation of Human Breast Cancer Tissue Samples	Journal of Proteome Research	11 (11)	5311-5322	2012
Muraoka S, Kume H, Watanabe S, Adachi J, Kuwano M, Sato M, Kawasaki N, Kodera Y, Ishitobi M, Inaji H, Miyamoto Y, Kato K and Tomonaga T	Strategy for SRM-based Verification of Biomarker Candidates Discovered by iTRAQ Method in Limited Breast Cancer Tissue Samples	Journal of Proteome Research	11 (8)	4201-4210	2012
Guo F., Hiroshima K., Wu D., Satoh M., Abulazi M., Yoshino I., Tomonaga T., Nomura F., Nakatani Y.	Prohibitin in squamous cell carcinoma of the lung: Its expression and possible clinical significance	Human pathology	43	1282-1288	2012
Hosako M., Muto T., Nakamura Y., Tsuta K., Tochigi N., Tsuda H., Asamura H., Tomonaga T., Kawai A., Kondo T.	Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker	J Proteomics	75	833-844	2012

Abulaizi M., Tomonaga T, Satoh M., Sogawa K., Matsushita K., Kodera Y., Obul J., Takano S., Yoshitomi H., Miyazaki M., Nomura F.	The Application of a Three-Step Proteome Analysis for Identification of New Biomarkers of Pancreatic Cancer	Int J Proteomics		Article ID 628787	2011
Wu D., Matsushita K., Matsubara H., Nomura F., Tomonaga T.	An alternative splicing isoform of eukaryotic initiation factor 4H promotes tumorigenesis in vivo and is a potential therapeutic target for human cancer	Int J Cancer	128	1018-1030	2011
Tonoike Y., Matsushita K., Tomonaga T, Katada K., Tanaka N., Shimada H., Nakatani, Y., Okamoto, Y., Nomura, F.	Adhesion molecule periplakin is involved in cellular movement and attachment in pharyngeal squamous cancer cells.	BMC Cell Biol	12	41	2011
Sogawa K., Kodera Y., Noda K., Ishizuka Y., Yamada M., Umemura H., Maruyama, K., Tomonaga, T., Yokosuka, O., Nomura, F.	The measurement of a fibrinogen alpha C-chain 5.9kDa fragment (FIC 5.9) using MALDI-TOF MS and a stable isotope-labeled peptide standard dilution	Clin Chim Acta	412	1094-1099	2011
Muto T., Taniguchi H., Kushima R., Tsuda H., Yonemori H., Chen C., Sugihara, Y., Sakamoto, K., Kobori, Y., Palmer, H., Nakamura, Y., Tomonaga, T., Tanaka, H., Mizushima, H., Fujita, S., Kondo, T.	Global expression study in colorectal cancer on proteins with alkaline isoelectric point by two-dimensional difference gel electrophoresis	J Proteomics	74	858-873	2011

Abe Y, Aly HH, Hiraga N, Imamura M, Wakita T, Shimotohno K, Chayama K, Hijikata M	Thromboxane A2 Synthase Inhibitors Prevent Production of Infectious Hepatitis C Virus in Mice With Humanized Livers	Gastroenterology	145	658-667	2013
Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, Shimotohno K	Hepatitis C Virus Infection Induces Inflammatory Cytokines and Chemokines Mediated by the Cross Talk between Hepatocytes and Stellate Cells	J. Virology	87	8169-8178	2013
Kuroki M, Ariumi Y, Hijikata M, Ikeda M, Dansako H, Wakita T, Shimotohno K, Kato N.	PML tumor suppressor protein is required for HCV production.	Biochem Biophys Res Commun	430	592-597	2013
Aly HH, Shimotohno K, Hijikata M, Seya T	In vitro models for analysis of the hepatitis C virus life cycle	Microbiol Immunol	56	1-9	2012
Ujino S, Nishitsuji H, Sugiyama R, Suzuki H, Hishiki T, Sugiyama K, Shimotohno K, Takaku H	The interaction between human initiation factor eIF3 subunit c and heat-shock protein 90: a necessary factor for translation mediated by the hepatitis C virus internal ribosome entry site	Virus Res	163	390-395	2012
Weng L, Tian X, Gao Y, Watashi K, Shimotohno K, Wakita T, Kohara M, Toyoda T	Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro	Biochim Biophys Acta	1820	1886-1892	2012

Hirata Y, Ikeda K, Sudoh M, Tokunaga Y, Suzuki A, Weng L, Ohta M, Tobita Y, Okano Ozeki K, Kawasaki K, Tsukuda T, Katsume A, Aoki Y, Umehara T, Sekiguchi S, Toyoda T, Shimotohno K, Soga T, Nishijima M, Taguchi R, Kohara M	Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis	PLoS Pathog	8	e1002860	2012

厚生労働科学研究費補助金

肝炎等克服緊急対策研究事業

肝移植後 C 型肝炎に対する治療法の標準化を目指した臨床的ならびに基礎的研究

平成 23-25 年度　　　総合研究報告書

【　研究成果の別刷（各 1 部）1 冊目/2 冊　　】

研究代表者　上本　伸二

平成 26（2014）年 6 月

BASIC AND TRANSLATIONAL—LIVER

Leptin Receptor Somatic Mutations Are Frequent in HCV-Infected Cirrhotic Liver and Associated With Hepatocellular Carcinoma

Atsuyuki Ikeda,[1] Takahiro Shimizu,[1] Yuko Matsumoto,[1] Yosuke Fujii,[1] Yuji Eso,[1] Tadashi Inuzuka,[1] Aya Mizuguchi,[1] Kazuharu Shimizu,[2] Etsuro Hatano,[3] Shinji Uemoto,[3] Tsutomu Chiba,[1] and Hiroyuki Marusawa[1]

Departments of [1]Gastroenterology and Hepatology and [3]Surgery, Graduate School of Medicine, and [2]Department of Nanobio Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan

BACKGROUND & AIMS: Hepatocellular carcinoma develops in patients with chronic hepatitis or cirrhosis via a stepwise accumulation of various genetic alterations. To explore the genetic basis of development of hepatocellular carcinoma in hepatitis C virus (HCV)-associated chronic liver disease, we evaluated genetic variants that accumulate in nontumor cirrhotic liver. **METHODS:** We determined the whole exome sequences of 7 tumors and background cirrhotic liver tissues from 4 patients with HCV infection. We then performed additional sequencing of selected exomes of mutated genes, identified by whole exome sequencing, and of representative tumor-related genes on samples from 22 cirrhotic livers with HCV infection. We performed in vitro and in vivo functional studies for one of the mutated genes. **RESULTS:** Whole exome sequencing showed that somatic mutations accumulated in various genes in HCV-infected cirrhotic liver tissues. Among the identified genes, the leptin receptor gene (*LEPR*) was one of the most frequently mutated in tumor and nontumor cirrhotic liver tissue. Selected exome sequencing analyses detected *LEPR* mutations in 12 of 22 (54.5%) nontumorous cirrhotic livers. In vitro, 4 of 7 (57.1%) *LEPR* mutations found in cirrhotic livers reduced phosphorylation of STAT3 to inactivate LEPR-mediated signaling. Moreover, 40% of Lepr-deficient (C57BL/KsJ-*db/db*) mice developed liver tumors after administration of thioacetamide compared with none of the control mice. **CONCLUSIONS:** Based on analysis of liver tissue samples from patients, somatic mutations accumulate in *LEPR* in cirrhotic liver with chronic HCV infection. These mutations could disrupt LEPR signaling and increase susceptibility to hepatocarcinogenesis.

Keywords: Liver Cancer; Whole Exome Sequencing; Genetics; STAT3.

C hronic inflammation plays an important role in the development of various human cancers. Indeed, many human cancers are closely associated with chronic inflammation, such as *Helicobacter pylori*–associated gastric cancer and inflammatory bowel disease–associated colorectal cancer.[1,2] On the other hand, tumor cells are believed to be generated by a stepwise accumulation of genetic alterations in various tumor-related genes during the process of inflammation-associated carcinogenesis.[3–6] Thus, it is reasonable to assume that somatic mutations latently accumulate in inflamed tissues, where the risk of tumorigenesis is high. Consistent with this hypothesis, several studies have shown frequent somatic mutations in nontumorous inflammatory tissues.[7,8] To clarify the mechanisms of inflammation-associated carcinogenesis, it is important to unveil the genetic alterations that occur in the inflamed tissues before tumor development. The diversity of mutated genes and the low frequency of genetic alterations compared with tumor tissues, however, are obstacles to revealing the landscape of accumulated genetic aberrations in chronically inflamed nontumorous tissues.

Several possible molecular mechanisms have been proposed for the genetic alterations occurring in the inflammatory condition.[9] We recently showed that the expression of activation-induced cytidine deaminase (AID), a DNA/RNA mutator enzyme family member, links inflammation to an enhanced susceptibility to genetic aberration during the development of various gastrointestinal and hepatobiliary cancers.[10–12] One clear example of inflammation-associated cancer is human hepatocellular carcinoma (HCC). HCC arises in the background of chronic inflammation caused by hepatitis C virus (HCV) infection.[13] We showed that aberrant AID expression triggered by HCV infection and the resultant inflammatory response leads to the generation of somatic mutations in various tumor-related genes in the inflamed liver tissues.[14,15] The target genes of AID-mediated mutagenesis in the inflamed hepatocytes, however, remain unclear.

Recent advances in sequencing technology have enabled us to reveal the whole picture of human genome sequences in association with the risk of development of a variety of human diseases, including cancers.[16,17] Whole exome capture

has identified several candidate driver genes in various human cancers.[18–20] Although deep sequencing on tumor tissues provides the most comprehensive analysis of the cancer genome, the genetic alterations accumulated in chronically inflamed tissues might provide an additional opportunity to clarify the early genetic changes required for carcinogenesis. In the present study, we applied whole exome sequencing to not only the tumor but also nontumorous liver tissues infected with HCV and found that somatic mutations of the leptin receptor gene (*LEPR*) latently underlie a subset of the cirrhotic liver tissues, providing the putative genetic basis for HCV-associated hepatocarcinogenesis.

Materials and Methods

Whole Exome Capture and Massively Parallel Sequencing

Massively parallel sequencing was performed as described previously.[21,22] Fragmented DNA (more than 5 μg) was used to prepare each DNA sequencing library. The DNA libraries were prepared according to the instructions provided with the Illumina Preparation Kit (Illumina, San Diego, CA). Whole exome sequence capture was then performed using SeqCap EZ Human Exome Library v2.0 (Roche, Madison, WI) according to the manufacturer's instructions. Cluster generation was performed on the Illumina cluster station (using their TruSeq PE Cluster Kit v5). Paired-end sequence for 2 × 76 base pairs was performed on the Illumina Genome Analyzer IIx (using their SBS Kits v5). Data collection and base calling were performed using SCS v2.9/RTA 1.9, and the resultant data files were converted to the FASTQ format.

Selected Exome Capture and Massively Parallel Sequencing

Fragmented DNA (1 μg) was used to prepare each DNA sequencing library. The DNA libraries were prepared using TruSeq DNA Sample Prep Kits (Illumina) according to the manufacturer's protocol. Selected gene capture (*TP53*, *CTNNB1*, *LEPR*) was performed using the SeqCap EZ Choice library (Roche) according to the manufacturer's recommendations. Cluster generation and multiplexed paired-end sequencing for 2 × 71 + 7 base pairs was performed as described previously. Data collection and base calling were performed as described previously and demultiplexed using CASAVA version 1.8.2 software (Illumina) with the default settings.

Sequence data analysis and variant filtering, patients, cell culture and transfection, immunoblotting analysis, and animal experiments are described in Supplementary Methods and Supplementary Figures 1 and 2.

Results

Whole Exome Sequencing Identified the Mutation Signature of Synchronous HCCs in Patients With Chronic HCV Infection

To explore the genetic basis of HCV-associated hepatocarcinogenesis, we first determined the whole exome sequences in matched pairs of HCC and background liver tissues obtained from 4 patients with chronic HCV infection

(Supplementary Table 1, patients 1–4). Three of these patients had multiple HCCs, and one had a solitary HCC in the liver. To compare the mutation signature in synchronous HCCs that developed in the same background liver, we determined the whole exome sequences of 2 representative HCCs in 3 cases and a solitary HCC in the remaining case (Figure 1). These 7 HCCs from 4 patients comprised 2 well-differentiated and 5 moderately differentiated HCCs, and the background liver tissue showed the histological characteristics of cirrhosis. To subtract the normal variants of each individual from the somatic mutations, we also determined the whole exome sequences of matched peripheral lymphocytes in each patient.

On average, we generated approximately 3.1 gigabases of sequence per sample, 80.1% of which were aligned with the human reference genome (Human Genome Build 37.3), and the mean coverage in the targeted regions was 33.8-fold (Supplementary Table 2). The variant filtering process is summarized in Supplementary Figure 1, and the overall error rate in our current platform was confirmed to be less than 0.2%, as described previously.[21] Overall, a total of 970 nucleotide positions in 768 different genes were mutated at a frequency of more than 20% of reads in the 7 HCC tissues (Supplementary Table 3). Among them, 79 genes were recurrently mutated in 2 or more tumor tissues (data not shown). These genes included representative tumor-related genes associated with HCC such as *TP53* (mutated in 2 of 7 tumors). Pathway analyses using Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/) revealed that metabolic pathway–related genes were most frequently damaged in HCC tissues (5 of 7 tumors) (Supplementary Table 4).

Interestingly, the mutation signature was remarkably different between the synchronously developed HCCs in each patient (Figure 1). In patient 3, none of the genes were commonly mutated in the 2 tumors examined, while 29 and 225 genes acquired independent somatic mutations in each tumor, respectively. In contrast, 32 genes (64.0% of mutated genes of HCC 1 in patient 1) and 9 (24.3% of mutated genes of HCC 1 in patient 2) were commonly mutated in the synchronously developed HCCs of those patients, indicating that the synchronous HCCs that developed in patient 1 or 2 shared a common pattern of genetic aberrations. These findings may suggest that the synchronous tumors in patients 1 and 2 were derived from common tumor-precursor cells or developed through intrahepatic metastasis, whereas the tumors in patient 3 developed independently in a multicentric manner.

Somatic Mutations Accumulated in the Cirrhotic Liver With HCV Infection

Whole exome sequencing also revealed a large number of nucleotide alterations in nontumorous cirrhotic liver tissues. In some cases, the total number of mutated genes in nontumorous liver was higher than that in tumor tissues, while the mutation frequency in nontumorous tissues tended to be lower than that in the matched tumor tissues (Figure 2). Sorting Intolerant From Tolerant (SIFT) functional impact predictions (http://provean.jcvi.org/index. php) revealed that the mean percentage of somatic

Patient #1

Patient #2

Figure 1. Schematic diagram showing the number of mutated genes in tumors and the number of genes commonly mutated in both tumor and the matched nontumorous liver tissues. Patients 1, 2, and 3 had synchronously developed HCCs, and patient 4 had a solitary HCC. Venn diagrams represent the number of mutated genes in each HCC tissue determined by whole exome sequencing. The numbers of genes commonly mutated in the synchronously developed multiple HCCs were 32, 9, and 0 in patients 1, 2, and 3, respectively. Among the mutated genes in HCC (at a frequency of more than 20% of reads), the number of genes commonly mutated in both HCC and matched nontumorous background liver (at a frequency of more than 5% of reads) is shown in *shaded circles*.

mutations predicted to be "damaging" in tumorous and nontumorous tissues was 20.4% and 13.1%, respectively, suggesting that somatic mutations that accumulated in nontumorous tissues included "passenger" mutations with less functional significance more frequently than those that accumulated in tumor tissues (Supplementary Table 3). We also identified a total of 448 indels in 7 HCC tissues (Supplementary Table 5), while fewer indels were detected in all of the nontumorous cirrhotic liver tissues examined (Supplementary Table 6). Consistent with previous studies,[19] we found that one-third of the mutations that accumulated in the exome sequences of HCC tissues were enriched as C>T; G>A transition, followed by A>G; T>C.

Similar to tumor tissues, C>T; G>A transition mutations were most frequently detected in nontumorous cirrhotic tissues (Supplementary Figure 3).

The aim of this study was to identify the somatic mutations in the nontumorous HCV-positive cirrhotic liver that may contribute to tumorigenesis. Therefore, we focused on the genes commonly mutated in both tumor and nontumorous liver tissues from the same patient. Because few genes commonly acquired somatic mutations with a frequency of more than 20% both in the tumor and the matched nontumorous liver tissues, we selected potential somatic mutations in nontumorous tissues that represented more than 5% of the total reads for further evaluation

Figure 2. The number of mutated genes and the distribution of mutation frequency in tumor and nontumorous cirrhotic liver tissues. The number of mutated genes (*upper panel*) and the distribution of mutation frequency (*lower panel*) detected by whole exome sequencing in each sample are shown (at a frequency of more than 20% of reads). Patients 1, 2, and 4 had more mutated genes in nontumorous liver tissue than those in HCC, while the mutation frequency at each nucleotide position in the majority of nontumorous cirrhotic liver tissues was <30%. NT, nontumorous cirrhotic liver.

(Supplementary Figure 1). The 5% threshold in nontumorous liver was chosen because common polymorphisms in each patient were excluded by determining the nucleotide changes with a frequency of more than 5% in the matched normal samples, such as peripheral lymphocytes.[18,23]

Based on these criteria, nucleotide positions that were commonly mutated in both the tumor (at a frequency of more than 20% of reads) and the matched background liver (at a frequency of more than 5% of reads)of each patient were detected (Figure 1). Among them, we focused on 40 mutations that result in amino acid changes (Supplementary Table 7) and found that only 2 genes, *LEPR* and *ZNF408*, were recurrently mutated with a frequency greater than 5% of reads in nontumorous cirrhotic livers from 2 of the 4 patients (listed as the top 2 genes in Supplementary Table 7). Of these 2 genes, we focused on *LEPR*, which has mutations that have been correlated with various human diseases, such as obesity and metabolic disorders.[24]

Identification of LEPR as the Recurrently Mutated Gene in Cirrhotic Livers With HCV Infection

We designed a selected sequence capture system that enabled us to enrich the whole exonic sequences of the

LEPR followed by deep sequencing. In addition, selected exonic capture of *TP53* and *CTNNB1*, the representative driver genes for hepatocarcinogenesis,[19,20,25] was performed on the same cohort. Accordingly, the selected exonic sequencing was applied to 22 additional HCV-positive cirrhotic liver tissues, 10 HCC tissues, and matched peripheral lymphocytes from 22 patients (Supplementary Table 1, patients 5–26). Selected exome sequencing generated a mean coverage of 996-, 1656-, and 2348-fold on *LEPR*, *TP53*, and *CTNNB1*, respectively (Supplementary Table 8). The variant filtering process is summarized in Supplementary Figure 2, and we detected both high-frequency (at a frequency of more than 20% of reads) and low-frequency (at a frequency of 1%–20% of reads) mutations separately.

High-frequency mutations in *TP53* and *CTNNB1* were detectable in 1 of 10 (10%) and 1 of 10 (10%) of the HCCs, respectively (Table 1), and these rates in the HCCs were consistent with recent deep-sequencing studies.[19,20] None of the nontumorous liver tissues possessed high-frequency mutations in *TP53* or *CTNNB1*; however, low-frequency mutations of *TP53* and *CTNNB1* were detected in 17 of 22 (77.3%) and 12 of 22 (54.5%) of the nontumorous livers, respectively. These findings indicated that somatic mutations in the representative cancer driver genes latently

Table 1. Number of Tumor Tissues and Nontumorous Cirrhotic Liver Tissues With Somatic Mutations at High and Low Frequencies in *TP53*, *CTNNB1*, and *LEPR*

	LEPR	TP53	CTNNB1
High-frequency mutations (>20%)			
Tumor (n = 10)	0	1	1
Nontumor (n = 22)	1[a]	0	0
Low-frequency mutations (1%–20%)			
Tumor (n = 10)	9	8	9
Nontumor (n = 22)	12[a]	17	12

[a]One patient had both high-frequency and low-frequency mutations in *LEPR*.

accumulated with a relatively low frequency in the cirrhotic livers with HCV infection.

Interestingly, we also found high- and/or low-frequency mutations in *LEPR* in both tumor and nontumorous liver tissues. Indeed, 9 of 10 (90%) tumors and 12 of 22 (54.5%) nontumorous cirrhotic livers possessed high- and/or low-frequency mutations in *LEPR* (Table 1). Notably, some somatic mutations were commonly detected in different positions of the same patient's liver. For example, C1084T (reference position: 65557165) mutations of *LEPR* were detected in the right, left, and caudate lobes of one patient (Supplementary Table 1, patient 11), suggesting that some of the hot spots of the acquired somatic mutations in the *LEPR* gene are commonly present in hepatocytes of the same liver underlying HCV infection. On the other hand, no mutations in *LEPR* were identified by deep sequencing analysis of noncirrhotic liver tissues from patients with chronic HCV infection or liver tissue from patients without HCV infection. (Supplementary Table 9). To confirm the somatic mutations present in *LEPR* in the nontumorous liver, we validated the candidate mutations by Sanger sequencing. For this purpose, we determined the sequences of exons 9 and 10 of *LEPR* of at least 50 randomly picked clones that were amplified from the nontumorous liver tissues of each patient. Although it was difficult to detect all the low-frequency mutations using the conventional cloning-sequencing method, we confirmed that somatic mutations were recurrently accumulated in *LEPR* of nontumorous cirrhotic liver tissues (Supplementary Figure 4).

LEPR Mutations Found in HCV-Positive Cirrhotic Liver Resulted in the Disruption of Downstream Signaling

Selected exome sequencing detected low-frequency mutations at a total of 650 nucleotide positions of *LEPR* in 12 of 22 (54.5%) HCV-positive cirrhotic liver tissues. Although the nucleotide changes were unevenly distributed throughout the whole *LEPR* exonic sequences, we detected 67 nucleotide alterations at the immunoglobulin (Ig) domain of *LEPR*, 38 of which (56.7%) were recurrently

mutated in 2 or more patients (Figure 3*A*). Among them, nonsynonymous mutations that caused the amino acid changes were detected at 62 of the 67 (92.5%) nucleotide positions, and 10 of the 62 were also mutated in at least one HCC tissue examined in this study. Histological examination revealed no significant association between the presence of *LEPR* mutations and the level of fatty changes in the liver tissue (data not shown).

To explore the functional relevance of *LEPR* mutations detected in HCV-positive cirrhotic liver tissues, we randomly selected 7 *LEPR*s with a mutated Ig domain from 62 nonsynonymously mutated *LEPR*s and examined the downstream signaling properties of the mutated *LEPR* in vitro.

Accordingly, we subcloned the mutated *LEPR*s and constructed expression plasmids encoding those mutant *LEPR*s (Figure 3*B*). We first confirmed that only a small amount of endogenous LEPR expression was observed in both HEK293 and HepG2 cells (Supplementary Figure 5) and the induction of the phosphorylation of STAT3 by wild-type *LEPR* in the presence of recombinant human leptin (Figure 3*C*). In contrast, 4 of 7 (57.1%) mutations in the Ig domain of *LEPR* resulted in the reduction or loss of STAT3 phosphorylation in vitro (Figure 3*C*). To clarify the functional significance of *LEPR* mutations, the cell proliferation rate was determined in HepG2 cells expressing either wild-type or mutated *LEPR*s that were identified in HCV-positive cirrhotic liver tissues using the lentivirus system.[26] Up-regulation of cyclin D1 and/or E transcripts as well as enhanced cell proliferation were observed in the cells with expression of the mutated *LEPR* gene compared with wild-type cells, while there was no difference in the expression levels and subcellular localization between wild-type and mutated LEPR protein (Supplementary Figure 6). These findings indicate that some of the somatic mutations that latently accumulated in the Ig domain of *LEPR* of the cirrhotic liver tissue might cause dysfunction of LEPR-mediated signaling in the cells with those somatic mutations.

LEPR Dysfunction Enhanced Susceptibility to Tumorigenesis

To determine the functional relevance of LEPR dysfunction on development of liver cancer, we examined whether disruption of the LEPR gene contributes to liver tumorigenesis using a genetically altered mouse model, the Lepr-deficient C57BL/KsJ-*db/db* mouse (hereafter referred to as *db/db* mouse).[27] Thioacetamide (TAA), a putative carcinogen, is well established to induce liver fibrosis and tumorigenesis in a murine model.[28] Thus, we conducted an assay to evaluate whether LEPR insufficiency alters the effects of TAA-mediated tumorigenesis. Accordingly, TAA was prepared at a concentration of 0.02%, a relatively low dose compared with the carcinogenic dose,[29] and administered in drinking water to mice for 24 weeks. The body weight of the *db/db* mice was about twice that of their lean littermates, and *db/db* mice had hepatomegaly even after normalizing the liver weight to the body weight (Figure 4*A*). Histological

Figure 3. Distribution of mutations in the *LEPR* sequence in HCV-positive cirrhotic liver tissues. (*A*) Schematic diagram of the LEPR gene (*top panel*) and the Ig domain (*middle panel*). Mutated positions in the Ig domain are indicated by *black triangles*. A total of 38 of 67 (56.7%) mutated nucleotide positions of the Ig domain were recurrently mutated in 2 or more HCV-positive cirrhotic liver tissues. Frequencies of non-synonymous (*black circles*) and synonymous (*gray diamonds*) mutations at each nucleotide position of the Ig domain of each sample are shown (*lower panel*). Nonsynonymous mutations were detected at 62 of the 67 nucleotide positions. (*B* and *C*) HEK293 cells were transfected with constructs encoding wild-type or representative various mutated *LEPR*s that were identified in HCV-positive cirrhotic liver tissues. Control: empty vector. (*B*) Immunoblotting was performed on the lysate of the cells expressing either wild-type or a mutated Ig domain (D332Y, V333A, Y426X, and V427M) of the *LEPR* gene using anti-Myc antibodies. (*C*) After transfection, the cells were treated with or without recombinant leptin protein. Total protein was isolated and immunoblot analysis was performed using anti–phospho-STAT3 (*upper panel*) and anti–total STAT3 (*lower panel*).

examination revealed the accumulation of lipids within individual hepatocytes in the *db/db* mouse liver, a typical feature of steatosis (Figure 4*A*).

After administering TAA, blood levels of alanine aminotransferase were substantially elevated in *db/db* mice compared with control mice (Supplementary Table 10).

Consistently, histological examination revealed that inflammatory activity was more severe in the liver of *db/db* mice than in the liver of control mice (Figure 4*B*). None of the control mice treated with TAA showed tumorigenesis 24 weeks after administration of TAA. In contrast, macroscopic liver nodules developed in 4 of 10 (40%) *db/db* mice

Figure 4. Tumors developed in *db/db* mice treated with TAA. (*A*) Representative macroscopic (*left panel*) and microscopic (*right panel*) images (H&E stain) of the liver from a *db/db* mouse and a littermate control mouse without administration of TAA. The liver of the *db/db* mouse is enlarged and yellowish compared with the control (*yellow arrowheads*). Histological analysis of the liver tissue of (*ii* and *iv*) *db/db* mouse and (*i* and *iii*) control mouse. Original magnification: 4× (*upper panels*) and 10× (*lower panels*). (*B*) Microscopic images (H&E stain) of (*i* and *iii*) control mice and (*ii* and *iv*) *db/db* mice treated with TAA for 24 weeks. In the *db/db* mice, inflammatory cell infiltration was extensively observed in the liver tissues underlying prominent steatosis (*ii* and *iv*). Original magnification: 4× (*upper panels*) and 20× (*lower panels*). (*C*) Microscopic images (H&E stain) of nodules that developed in *db/db* mice treated with TAA for 24 weeks (*i–vi*). Liver cancers developed in 2 *db/db* mice (*i–iv*). *Arrowheads* indicate hepatocyte hyperplasia (*v* and *vi*). Original magnification: 4× (*left panels*) and 10× (*right panels*).

that received the same dose of TAA during the same observation period (Table 2). Histological examination revealed that 2 *db/db* mice with liver nodules developed well-differentiated HCC (Figure 4*C*). In addition, the remaining nodules that developed in *db/db* mouse liver showed features of hepatocyte hyperplasia. These findings